SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

LaBarre Michael J.

(Last)

(First)

(Middle)

C/O HALOZYME THERAPEUTICS, INC.

11388 SORRENTO VALLEY ROAD

(Street)

SAN DIEGO

92121

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/03/2020

3. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Chief Technical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	154,223	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Option to Purchase Common Stock	02/03/2012⁽¹⁾	02/03/2021	Common Stock	40,000	$7.14	D
Option to Purchase Common Stock	02/02/2013⁽¹⁾	02/02/2022	Common Stock	40,000	$11.29	D
Option to Purchase Common Stock	02/04/2014⁽¹⁾	02/04/2023	Common Stock	55,000	$6.55	D
Option to Purchase Common Stock	02/06/2015⁽¹⁾	02/06/2024	Common Stock	37,500	$13.1	D
Option to Purchase Common Stock	02/04/2016⁽¹⁾	02/04/2025	Common Stock	34,000	$13.81	D
Option to Purchase Common Stock	02/03/2017⁽¹⁾	02/03/2026	Common Stock	78,452	$8.11	D
Option to Purchase Common Stock	02/22/2018⁽¹⁾	02/22/2027	Common Stock	56,352	$12.07	D
Option to Purchase Common Stock	02/14/2019⁽¹⁾	02/14/2028	Common Stock	40,489	$18.41	D
Option to Purchase Common Stock	07/02/2019⁽¹⁾	07/02/2028	Common Stock	2,000	$16.78	D
Option to Purchase Common Stock	02/12/2020⁽¹⁾	02/12/2029	Common Stock	60,146	$16.65	D
Restricted Stock Unit	02/03/2017⁽²⁾	⁽²⁾	Common Stock	11,559	⁽²⁾	D
Restricted Stock Unit	02/22/2018⁽²⁾	⁽²⁾	Common Stock	17,606	⁽²⁾	D
Restricted Stock Unit	02/14/2019⁽²⁾	⁽²⁾	Common Stock	17,314	⁽²⁾	D
Restricted Stock Unit	02/12/2020⁽²⁾	⁽²⁾	Common Stock	31,532	⁽²⁾	D

Explanation of Responses:

1. This option vests one-fourth on such date and then vests 1/48th monthly thereafter.

2. One-fourth of the original grant vests on such date and one-fourth vests annually thereafter. Represents a restricted stock unit award with no exercise price.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ James R. Oehler as attorney-in-fact for Michael J. LaBarre	01/06/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.